Study the pathological features of diseases using induced pluripotent stem cells derived form patient's somatic cells

The limited experimental access to disease-affected human tissues has severely impeded the elucidating of molecular mechanisms underlying disease development. Generation of induced pluripotent stem cells (iPSCs) by over-expression of defined transcription factors in somatic cells, in particular in those from patient somatic cells, presents an attractive and promising approach to model the early stages of diseases in vitro and to screen novel biomarkers as well as therapeutic medicines. Recently, many research groups have independently reported that patient-specific iPSC-derived cells recapitulated multiple features of pathological events of a particular disease, offering experimental evidence of utilizing patient-specific iPSCs to model diseases and reevaluate the current therapies. We have derived iPSC lines using somatic cells of patients suffering from Klinefelter's Syndrome (KS) and Alzheimer's Disease (AD) and explored the possibility to use these iPSC lines to recapitulate the pathological features of the diseases. Our results show that patient's specific iPSC lines provide good opportunity to study the development and treatment of diseases.

sRNA Induces the Large-scale Transdetermination of Mesenchymal Stem Cells into Hematopoietic Stem Cells in Human.

Mesenchymal stem cells (MSCs) can differentiate into cells of bone, endothelium, adipose tissue, cartilage, muscle, and brain. However, whether they can transdeterminate into hematopoietic stem cells (HSCs) remains unsolved. We report here that a subpopulation of human MSCs that are CD44+,CD29+, CD105+, CD166+,CD133-,CD34- could differentiate into hematopoietic stem cells (CD150+/CD133+/CD34+) and their descending blood cells in vitro, when transfected with new endogenous shRNAs The sRNA was high-effectively delivered into MSCs by a novel peptide means. These induced MSC-HSCs could form different types of hematopoietic colonies as nature-occurring HSCs did. Upon transplantation into sublethally irradiated NOD/SCID mice, these MSC-HSCs engrafted and differentiated into all hematopoietic lineages such as erythrocytes, lymphocytes, myelocytes and thrombocyte. More importantly, these induced HSCs could successfully engraft and effectively function in patients with severe aplastic anemia. Furthermore, we demonstrated the first evidence that the transdetermination of MSCs was induced by acetylation of histone proteins and activation of many transcriptional factors. Together, our findings identify the sRNAs that dictates a directed differentiation of MSCs toward HSCs and open up a new source for HSCs used for the treatment of blood diseases and artificial stem cell-made blood.

yy

immunotherapy against cancers(position of sellular therapy)

Study the pathological features of diseases using induced pluripotent stem cells derived form patient's somatic cells

The limited experimental access to disease-affected human tissues has severely impeded the elucidating of molecular mechanisms underlying disease development. Generation of induced pluripotent stem cells (iPSCs) by over-expression of defined transcription factors in somatic cells, in particular in those from patient somatic cells, presents an attractive and promising approach to model the early stages of diseases in vitro and to screen novel biomarkers as well as therapeutic medicines. Recently, many research groups have independently reported that patient-specific iPSC-derived cells recapitulated multiple features of pathological events of a particular disease, offering experimental evidence of utilizing patient-specific iPSCs to model diseases and reevaluate the current therapies. We have derived iPSC lines using somatic cells of patients suffering from Klinefelter's Syndrome (KS) and Alzheimer's Disease (AD) and explored the possibility to use these iPSC lines to recapitulate the pathological features of the diseases. Our results show that patient's specific iPSC lines provide good opportunity to study the development and treatment of diseases.

Novel signaling by the IKK complex

Signal transduction plays a pivot role in regulating cell functions, from proliferation, differentiation, programmed cell death, and transformation. Deregulation of signal transduction could lead to various human diseases even cancer. Extracellular signals are transmitted into cells via an intracellular signaling network that is composed of multiple signaling pathways, dictating cellular functions, such as growth, differentiation, programmed death (apoptosis) and transformation.
Although we have learnt a great deal about the architecture of the intracellular signaling network, our understanding of its biology is limited. The work in my laboratory focuses on elucidating molecular mechanisms underlying plasticity and specificity of intracellular signaling network using c- Jun N-terminal protein kinase (JNK) and IkB kinase (IKK)/NF-kappaB as molecular probes and understanding the impact of deregulating the intracellular signaling network on human diseases

yuji Heike：免疫治疗（治疗癌症的sellular位置）

国际癌症中心（NationalCancerCenter）的yujiHeike教授则带来了癌症的细胞免疫治疗方法。他认为今后组合疗法是癌症治疗的主流方法，并对癌症免疫疗法进行了详细介绍。以PD-1在肺癌中的免疫疗法为案例进行了详细阐述。最后他还号召全亚洲能够加入ACTO，共同合作研究。

Quyen Nguyen:荧光手术

医学教科书为人体各组织标上颜色以便未来的外科医生学习，而真实的人体组织却不是那样的。但是现在情况改变了。在TEDMED 上，Quyen Nguyen 向大家展示分子是如何照亮肿瘤使其呈氖绿色，向外科医生标明确切需要切除的部位。

y

y